Key result
IL-1β inhibition improves cardiovascular outcomes, supporting anti-inflammatory strategies in atherosclerosis.
Why the study?
Inflammatory pathways drive atherogenesis and link conventional risk factors to atherosclerosis and its complications, highlighting interleukin-1 beta as a therapeutic target in cardiovascular disease.
Interleukin-1 beta is a key inflammatory mediator in atherosclerosis, and targeting it represents a promising therapeutic strategy to improve cardiovascular outcomes.
Answers are grounded in this paper and cite their sources.
May support biomarker-guided IL-1β therapy in atherosclerosis; leaves open optimal use pending dedicated randomized trials.
Inflammatory pathways drive atherogenesis and link conventional risk factors to atherosclerosis and its complications. One inflammatory mediator has come to the fore as a therapeutic target in cardiovascular disease. The experimental and clinical evidence reviewed here support interleukin-1 beta (IL-1β) as both a local vascular and systemic contributor in this regard. Intrinsic vascular wall cells and lesional leukocytes alike can produce this cytokine. Local stimuli in the plaque favor the generation of active IL-1β through the action of a molecular assembly known as the inflammasome. Clinically applicable interventions that interfere with IL-1 action can improve cardiovascular outcomes, ushering in a new era of anti-inflammatory therapies for atherosclerosis. The translational path described here illustrates how advances in basic vascular biology may transform therapy. Biomarker-directed application of anti-inflammatory interventions promises to help us achieve a more precise and personalized allocation of therapy for our cardiovascular patients.
No takes yet. Share an insight, caveat, or question.
Peter Libby (2017) conducted a review in Atherosclerosis. Anti-inflammatory therapies targeting Interleukin-1 beta (IL-1β) was evaluated. Interventions targeting interleukin-1 beta (IL-1β) can improve cardiovascular outcomes, supporting the use of anti-inflammatory therapies for atherosclerosis.
Synapse has enriched 10 related papers. Consider them for comparative context: